Efficacy of Ado-trastuzumab emtansine

Ado-trastuzumab emtansine was evaluated in two Herceptin-responsive and one Herceptin-resistant breast tumor models. In the Herceptin response model, trastuzumab led to complete tumor regression in all mice, while Herceptin alone slowed tumor growth.

Trastuzumab has been shown to significantly delay disease progression and extend survival in patients with HER2-expressing advanced and metastatic breast cancer who were previously treated with trastuzumab and a taxane. In a major study of 991 such patients, those treated with trastuzumab lived an average of 9.6 months without their disease worsening, compared with an average of 6.4 months for patients treated with capecitabine and lapatanib, two other cancer drugs. Patients who received trastuzumab also survived 31 months, while patients who received capecitabine and lapatinib survived 25 months.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.